Spermatogenesis is a complex process of terminal differentiation by which mature sperms are generated,and it can be divided into three phases：mitosis,meiosis and spermiogenesis.In a previous study,we established a se...Spermatogenesis is a complex process of terminal differentiation by which mature sperms are generated,and it can be divided into three phases：mitosis,meiosis and spermiogenesis.In a previous study,we established a series of proteomic profiles for spermatogenesis to understand the regulation of male fertility and infertility.Here,we further investigated the localization and the role of flotillin-2 in spermiogenesis.Flotillin-2 expression was investigated in the testis of male CD1 mice at various developmental stages of spermatogenesis by using Western blotting,immunohistochemistry and immunofluorescence.Flotillin-2 was knocked down in vivo in three-week-old male mice using intratesticular injection of small inhibitory RNA（siRNA）,and sperm abnormalities were assessed three weeks later.Flotillin-2 was expressed at high levels in male germ cells during spermatogenesis.Flotillin-2 immunoreactivity was observed in pachytene spermatocytes as a strong dot-shaped signal and in round spermatids as a sickle-shaped distribution ahead of the acrosome.Immunofluorescence confirmed flotillin-2 was localized in front of the acrosome in round spermatids,indicating that flotillin-2 was localized to the Golgi apparatus.Knockdown of flotillin-2 in vivo led to a significant increase in head sperm abnormalities isolated from the cauda epididymis,compared with control siRNA-injected testes.This study indicates that flotillin-2 is a novel Golgi-related protein involved in sperm acrosome biogenesis.展开更多
目的:对比研究FLOT方案与FOLFOX方案治疗中晚期胃癌(GC)的近远期疗效及对血清肿瘤标志物和NRP-2的影响。方法:选入我院2020年3月~2022年2月收治的82例中晚期GC患者,根据化疗方法不同分为FLOT组和FOLFOX组,各41例。比较两组的近远期疗效...目的:对比研究FLOT方案与FOLFOX方案治疗中晚期胃癌(GC)的近远期疗效及对血清肿瘤标志物和NRP-2的影响。方法:选入我院2020年3月~2022年2月收治的82例中晚期GC患者,根据化疗方法不同分为FLOT组和FOLFOX组,各41例。比较两组的近远期疗效、血清肿瘤标志物和NRP-2水平;随访至2023年11月,记录两组患者生存状态并绘制Kaplan-Meier生存曲线。结果:FLOT组客观有效率显著高于FOLFOX组(85.37%vs.65.85%,P<0.05)。FLOT组治疗后血清癌胚抗原[(12.77±1.85)ng/m L vs.(20.69±2.58)ng/mL]、糖类抗原19-9[(20.46±5.20)U/m L vs.(29.41±8.04)U/m L]、糖类抗原125[(14.90±5.61)U/m L vs.(20.72±6.23)ng/mL]和NRP-2[(13.01±2.11)ng/mL vs.(15.23±2.25)ng/mL]水平均显著低于FOLFOX组,PFS[12.900(95%CI:12.183~13.617)个月vs.9.600(95%CI:8.471~10.729)个月]和OS[28.103(95%CI:25.209~30.996)个月vs.20.799(95%CI:18.482~23.115)个月]显著长于FOLFOX组(P<0.05)。两组疾病控制率和毒副反应发生率无显著差异(P>0.05)。结论:FLOT方案和FOLFOX方案均是中晚期GC的有效化疗方案,安全性一致,但前者在提高客观有效率、降低血清肿瘤标志物和NRP-2水平、延长生存期方面更具优势。展开更多
基金supported by a grant from the National Basic Research Program of China(973 Program)(No.2011CB944301)
文摘Spermatogenesis is a complex process of terminal differentiation by which mature sperms are generated,and it can be divided into three phases：mitosis,meiosis and spermiogenesis.In a previous study,we established a series of proteomic profiles for spermatogenesis to understand the regulation of male fertility and infertility.Here,we further investigated the localization and the role of flotillin-2 in spermiogenesis.Flotillin-2 expression was investigated in the testis of male CD1 mice at various developmental stages of spermatogenesis by using Western blotting,immunohistochemistry and immunofluorescence.Flotillin-2 was knocked down in vivo in three-week-old male mice using intratesticular injection of small inhibitory RNA（siRNA）,and sperm abnormalities were assessed three weeks later.Flotillin-2 was expressed at high levels in male germ cells during spermatogenesis.Flotillin-2 immunoreactivity was observed in pachytene spermatocytes as a strong dot-shaped signal and in round spermatids as a sickle-shaped distribution ahead of the acrosome.Immunofluorescence confirmed flotillin-2 was localized in front of the acrosome in round spermatids,indicating that flotillin-2 was localized to the Golgi apparatus.Knockdown of flotillin-2 in vivo led to a significant increase in head sperm abnormalities isolated from the cauda epididymis,compared with control siRNA-injected testes.This study indicates that flotillin-2 is a novel Golgi-related protein involved in sperm acrosome biogenesis.
文摘目的:对比研究FLOT方案与FOLFOX方案治疗中晚期胃癌(GC)的近远期疗效及对血清肿瘤标志物和NRP-2的影响。方法:选入我院2020年3月~2022年2月收治的82例中晚期GC患者,根据化疗方法不同分为FLOT组和FOLFOX组,各41例。比较两组的近远期疗效、血清肿瘤标志物和NRP-2水平;随访至2023年11月,记录两组患者生存状态并绘制Kaplan-Meier生存曲线。结果:FLOT组客观有效率显著高于FOLFOX组(85.37%vs.65.85%,P<0.05)。FLOT组治疗后血清癌胚抗原[(12.77±1.85)ng/m L vs.(20.69±2.58)ng/mL]、糖类抗原19-9[(20.46±5.20)U/m L vs.(29.41±8.04)U/m L]、糖类抗原125[(14.90±5.61)U/m L vs.(20.72±6.23)ng/mL]和NRP-2[(13.01±2.11)ng/mL vs.(15.23±2.25)ng/mL]水平均显著低于FOLFOX组,PFS[12.900(95%CI:12.183~13.617)个月vs.9.600(95%CI:8.471~10.729)个月]和OS[28.103(95%CI:25.209~30.996)个月vs.20.799(95%CI:18.482~23.115)个月]显著长于FOLFOX组(P<0.05)。两组疾病控制率和毒副反应发生率无显著差异(P>0.05)。结论:FLOT方案和FOLFOX方案均是中晚期GC的有效化疗方案,安全性一致,但前者在提高客观有效率、降低血清肿瘤标志物和NRP-2水平、延长生存期方面更具优势。
